Q4 2024 Aurora Spine Corp Earnings Call Transcript
Key Points
- Aurora Spine Corp (ASAPF) reported a 21% increase in revenue for fiscal year 2024, marking a significant achievement.
- The SiLO TFX system experienced a remarkable 135% increase in revenues, highlighting strong product adoption.
- The company achieved its first full year of positive EBITDA, indicating improved financial health.
- Aurora Spine Corp (ASAPF) successfully expanded its internal sales team to 14 people, enhancing its sales capabilities.
- The company received FDA clearance for the Aero fusion system, a new product with promising market potential.
- Operating expenses increased to $3.22 million in Q4 2024, up from $2.58 million in Q4 2023, due to costs associated with training and sales expansion.
- The company reported a net loss of $0.653 million for Q4 2024, compared to a loss of $0.285 million in Q4 2023.
- EBITDAC was negative $0.32 million for Q4 2024, indicating challenges in maintaining profitability.
- The accounts receivable balance remains a focus, with efforts needed to improve cash collections.
- There is potential for margin compression due to the distributor model, which could impact profitability.
Good day and welcome to the Aurora Spine 4th quarter and Financial year 2024 results conference call.
(Operator Instructions)
Please note this event has been recorded.
I would now like to turn the conference over to Adam Lowensteiner with Liam Partners. Please go ahead.
Thank you, Jacob. Welcome everyone, and thank you for joining us today to conduct an update with investors and review the financial results Aurora Spine for the 4th quarter and fiscal year 2024 ended December 31, 2024. With us on the call representing the company today are Mr. Trent Northcutt , President and CEO of Aurora Spine, and Mr. Chad Clouse , Chief Financial Officer of Aurora Spine.
Before we begin, I would like to remind everyone that statements made during the course of this call may be considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1,933 as amended and Section 21A of the Securities Act of 1,934.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
